Roche launches ‘next-generation’ blood glucose monitoring system
pharmafile | August 23, 2016 | News story | Manufacturing and Production, Sales and Marketing | Roche, blood glucose monitoring, diabetes
Roche has announced the launch of its new Accu-Chek Guide blood glucose monitoring system. The system promises to simplify everyday blood glucose (BG) monitoring by providing features including a spill-resistant SmartPack test strip vial and improved accuracy and diabetes management.
The system features Bluetooth Low Energy connectivity to the Accu-Chek Connect diabetes management mobile app, a cloud-based solution which securely and automatically logs user data ready for sharing by patients, caregivers and healthcare professionals, allowing on-the-go monitoring and advice. In a recent study, 97% of 197 participants found this system allows for a better, easy-to-use testing experience.
The unit also features on-board pattern detection which helps identify extreme glucose deviations and delivers tighter 10/10 accuracy for greater reliability of results; studies have demonstrated that approximately just half of BG meters evaluated meet minimum accuracy requirements as defined by the ISO 15197:2013/EN ISO 15197:2015 standard.
“As the global leader in diabetes management we are dedicated to supporting people with diabetes, in thinking less about their daily therapy routines. We are very excited to introduce this innovative system, that simplifies blood glucose monitoring and improves the testing experience,” says Roland Diggelmann, CEO at Roche Diagnostics.
The new system is set to launch in Denmark, Switzerland and Australia, with more countries to follow starting in early 2017.
Matt Fellows
Related Content
Roche receives CE Mark for blood test to help rule out Alzheimer’s
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …
MetP Pharma releases positive data on intranasal semaglutide administration
MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering …
Roche candidate shows early promise for treating haemophilia A
Roche has announced encouraging early results from its phase 1/2 trial of NXT007, an investigational …
